Welcome to our dedicated page for Callan JMB news (Ticker: CJMB), a resource for investors and traders seeking the latest updates and insights on Callan JMB stock.
Callan JMB Inc. provides integrative logistics services for healthcare organizations and emergency management agencies, including fulfillment, storage, monitoring, cold-chain logistics and specialized distribution. Company updates commonly address emergency preparedness contracts, reverse distribution of vaccines and pharmaceuticals, regulated product handling, government relationships and business updates tied to healthcare supply-chain resilience.
Recurring developments also include the Atlas Complex in Marion, Alabama, a medical, pharmaceutical and logistics campus supporting QA/QC, cold-chain logistics, warehousing and domestic distribution. Other updates cover pharmaceutical onshoring initiatives, independent manufacturing oversight, quality-control governance, collaboration activity with life-sciences partners, financial results, investor communications and legal or listing-related corporate matters.
Callan JMB (NASDAQ: CJMB) announced the Atlas Complex, a planned 150-acre multi-use pharmaceutical, logistics and life-sciences campus in Marion, Alabama, launched April 20, 2026.
The project includes a partnership with Walker’s Pharmaceuticals of India, adaptive reuse of historic infrastructure, pursuit of a Foreign-Trade Zone subzone, and expectations to create approximately 250–300 jobs while supporting onshoring, QA/QC, cold-chain logistics, and domestic distribution.
Summary not available.
Callan JMB (NASDAQ:CJMB) executed rapid reverse distribution of critical vaccines and pharmaceuticals to multiple jurisdictions on April 7, 2026 under a longstanding Public Health Emergency Preparedness contract. The company coordinated receipt, inspection, cold-chain storage and thermal-shipping deployment to redirect short-dated inventory to areas experiencing localized outbreaks.
This redistribution aims to preserve product integrity, avoid waste, and support fiscal stewardship of federal funds by moving usable stock from holding jurisdictions to points of dispensing per public health leadership direction.
Callan JMB (NASDAQ: CJMB) reported full‑year 2025 results and provided a business update on March 31, 2026. Revenue was $5.7M versus $6.6M in 2024; gross profit $2.1M and loss from operations $7.0M. Cash and cash equivalents were $2.1M.
The company highlighted new commercial agreements including a manufacturing oversight deal with Attune, a joint venture with Revival Health, expansion into India, renewed government contracts (Chicago and Oregon), vaccine lease programs, and an upgraded Sentry Monitoring System.
Callan JMB (NASDAQ: CJMB) announced independent infrastructure and oversight support for U.S. scale-up of the JKB-122 (Lodonal™) immune restoration platform on March 27, 2026.
Callan JMB will validate manufacturing, quality systems, and supply chain readiness to support Phase 2b/3 clinical advancement, U.S. GMP scale-up, and alignment with BARDA, DoD, and VA federal standards.
Callan JMB (NASDAQ: CJMB) will oversee manufacturing, quality assurance, and distribution governance for Attune Biotech's investigational drug lodonal™ (JKB-122) under IND 181314 for the treatment of Long COVID.
Services include CMO qualification, batch record review, supply chain verification, surge capacity assessment, and distribution pathway validation. Attune plans a randomized Phase 2b/3 trial; lodonal™ remains investigational and is protected by IP through 2041.
Callan JMB (NASDAQ:CJMB) announced that Founder, CEO and Chairman Wayne Williams will attend the 50th International GMP Conference on March 2-5, 2026 in Athens, Georgia.
The conference, co-sponsored by the University of Georgia College of Pharmacy and the FDA, focuses on pharmaceutical regulation, technology and supply-chain integrity.
Callan JMB (NASDAQ: CJMB) will participate in the iAccess Alpha Virtual Best Ideas Spring Investment Conference on March 10–11, 2026. The company will present virtually on March 10, 2026 at 10:30am ET. A webcast will be available at the provided link.
Investors can access the live webcast or contact iAccess Alpha or KCSA Strategic Communications for more information.
Callan JMB (NASDAQ:CJMB) will participate in the DealFlow Discovery Conference on January 28-29, 2026 at The Borgata, Atlantic City, NJ. The company is scheduled to present on Wednesday, January 28 at 3:00pm in Room #3. Callan JMB provides fulfillment, storage, monitoring, and cold chain logistics services for healthcare and emergency management agencies. For attendance or media queries, contact your DealFlow representative or email CallanJMB@kcsa.com.
Callan JMB (NASDAQ:CJMB) signed a strategic teaming agreement with Attune Biotech on Jan 15, 2026 to provide manufacturing oversight, federal deployment coordination, and commercialization support for Attune's multi-asset therapeutic pipeline. The parties expect approximately $50–$75 million in combined revenue over the next 5 years, with Callan JMB's share projected at about $25–$45 million depending on 50% or 60% profit-sharing by contract scope. Callan JMB cites validated surge-readiness capacity (a 500,000-unit simulation), 24-hour emergency deployment capability and Regional CONUS distribution within 48 hours, aiming to accelerate Attune's federal SNS integration and BARDA/DoD/VA procurement readiness.